Michael Hofman (@DrMHofman) / X

Michael Hofman

2,631 posts

Michael Hofman

@DrMHofman

Working together to improve patient outcomes with personalised medicine & precision oncology: theranostics. PET/CT, prostate cancer ☢️ Prof 🇦🇺

Melbourne, Victoria

Joined December 2013

Michael Hofman
@DrMHofman
Apr 13, 2024
ENZA-P in @TheLancetOncol Lu-177 PSMA-617 + enzalutamide vs. enza alone: ● ↑PFS: 13.0 vs 7.8, hazard radio 0.43 ● PSA90 response 78% vs 37% ● PSA50 response 93% vs. 68% ● no additional side effects Incredible work from @drlouiseemmett @Prof_IanD & @ANZUPtrials team
21K
Michael Hofman
@DrMHofman
Feb 24, 2023
Another extraordinary day at @PeterMacCC. We gave cycle #17 of Lu-177 PSMA-617 to a patient with prostate cancer. Continues to benefit 4+ years. Bloods and renal function normal. Even more extraordinary, We were both wearing the same socks. @pros_tic
18K
Michael Hofman
@DrMHofman
Feb 18, 2023
Reading the NCCN v1.2023 prostate cancer guidelines and noting this change of wording: "Ga-68 PSMA-11 or F-18 piflufolastat PSMA PET/CT or PET/MRI are preferred for bone and soft tissue (full body) imaging.". No longer an "alternative". Now preferred.
20K
Michael Hofman
@DrMHofman
Mar 10, 2023
1/ #LuTectomy #EAU23 Game Changing Session: first use of Lu-177 PSMA-617 first-line in patients with high-risk localised N0/N1 prostate cancer: 20pt. 1-2 cycles→prostatectomy. ☢36Gy. 45% PSA50-RR. Safe. Few toxicities. @RenuEapen @declangmurphy @Uroweb
GIF
32K
Michael Hofman
@DrMHofman
Aug 7, 2024
Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer rdcu.be/dQg5y Congrats @RenuEapen for leading this work just published in @Nature Reviews Urology @declangmurphy @lewisjwau @lawrentschuk @gu_onc
17K
Michael Hofman
@DrMHofman
Jun 5, 2022
SUVmean > 10 on PSMA PET in the Vision trial had improved OS and PFS. It's extraordinary that we found the same cut-off in our ph2 @PeterMacCC study and @ANZUPtrials #TheraP study. **WE HAVE A NEW BIOMARKER** #ASCO22 @ASCO
Michael Hofman
@DrMHofman
Mar 17, 2022
Introducing the new PRIMARY score for reporting PSMA PET: using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer DIAGNOSIS. We feel this is MAJOR advance for interpretation of PSMA PET. jnm.snmjournals.org/content/early/… @drlouiseemmett @JournalofNucMed
Michael Hofman
@DrMHofman
Feb 17, 2022
1/ Hot of the press: #TheraP Imaging Biomarkers presented @asco #GU21. PSMA PET is a PREDICTIVE biomarker: patients randomised to Lu-PSMA-617 with very high PSMA expression on PSMA PET had a 91% PSA RESPONSE RATE (PSA decline>50%). @ANZUPtrials @TrialsCentre
Michael Hofman
@DrMHofman
Apr 8, 2023
Diagnostic Accuracy of PSMA PET/CT for Initial Staging of Intermediate to High-risk Prostate Cancer: Systematic Review and Meta-analysis "PSMA-PET should be used as a first-line approach for the initial staging of PCa." sciencedirect.com/science/articl… @EUplatinum @declangmurphy
16K
Michael Hofman
@DrMHofman
Jul 14, 2024
Probably the best current review on PSMA expression ... congrats to @mishabeltran @mkbakht nature.com/articles/s4158…
Misha Beltran
@mishabeltran
Jul 9, 2024
Check out our new review in @NatRevUrol on biologic determinants of PSMA expression, regulation, and heterogeneity in prostate cancer led by @mkbakht @DanaFarber_GU @PCF_Science Link to paper: rdcu.be/dM7GF nature.com/articles/s4158…
29K
Michael Hofman
@DrMHofman
Mar 5, 2022
THE HISTORY OF PSMA THERANOSTICS in this months @JournalofNucMed jnm.snmjournals.org/content/63/3/3… I think the 2022 headline will be FDA approval of Lu-177 PSMA-617 @PCF_Science @soulehoward1 @AndreaMiyahira @pros_tic
Michael Hofman
@DrMHofman
Feb 23, 2024
New radiotracer for clear cell renal carcinoma - CA-9 targeting peptide: SUVs >100 in tumor in first 3 patients with low background activity = WOW !! jnm.snmjournals.org/content/early/… @DebiopharmNews @DrBenTran @JournalofNucMed @PeterMacRes
11K
Michael Hofman
@DrMHofman
May 31, 2025
Pleased to share some first images of Lutetium-177 CA-IX peptide theranostics for metastatic clear cell renal cancer #ASCO25 @ASCO. Ga-68 DPI-4452 PET/CT at baseline and on-treatment shown👇 State-of-the-Science: Novel Diagnostics and Therapeutics in Renal Cell Carcinoma
GIF
14K
Michael Hofman
@DrMHofman
May 3, 2025
Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival data. Superior to NCCN risk score. Data across initial stage, biochemical recurrence, "non-metastatic" castration-resistant, mSPC, MCRPC !! Just out in
11K